14 August 2026

Eli Lilly, which makes some of the biggest weight-loss drugs, sued six US businesses this week for selling a drug that no regulator anywhere has approved. Four of the six trade under "peptide" brand names — peptides are experimental drugs made of short protein fragments, used for recovery and longevity. Lilly says it has also reported more than 14,000 websites and ads to authorities.

Chasing that story, we found something we should have found in June. The New York Times ran a feature on this exact black market on 18 June. We have spent eleven mornings writing that no major paper had covered it. One had. We are flagging our own miss rather than quietly correcting it.

Separately, a large study links hormone therapy in menopause to less Alzheimer's damage found in the brain after death.

Nothing overdue; next horizons are 2026-12-31 (three rows) and 2027-03-31.

One resolution candidate, needing a decision rather than a date. `peptide-safety-incident` may have resolved TRUE on 2026-06-18. The blocker is the rubric, not the evidence: nobody wrote down whether a market-and-danger feature about a peptide sold as a weight-loss drug counts as "a major feature on peptide injuries, contamination, or deaths." Two separable calls — does this piece meet the bar, and what is the bar.